
Sign up to save your podcasts
Or


Amgen's [BiTE]® technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE® platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Binrholz is joined by Dr. Ajai Chari.
USA-OCF-80679
By ReachMD4.5
22 ratings
Amgen's [BiTE]® technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE® platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Binrholz is joined by Dr. Ajai Chari.
USA-OCF-80679

39 Listeners

10 Listeners

59 Listeners

1,148 Listeners

195 Listeners

45 Listeners

7 Listeners